Highest-materiality recent filing
Catheter Precision invests $1M in Volato Group, receives SOAR and flyExclusive shares
Purchases 2,941,176 SOAR shares at $0.34/share ($1M) in a private placement.
Q1 revenue $432K (200% YoY) driven by medical device segment (+73%) and new Flyte aviation platform.
Catheter Precision closes $3.47M Series C-2 preferred; issues $11M Series D for Flyte acquisition
3,470 shares of Series C-2 Preferred at $1,000 stated value sold for gross proceeds of $3,470,000.
Catheter Precision shareholders approve reverse split (1:2-1:100) and preferred share issuances
All six proposals passed at April 15 special meeting; 49.5% of outstanding shares voted.
Catheter Precision FY2025 rev +95% to $819K; net loss $17.2M; acquires Flyte aviation platform
Revenue $819K in FY2025, up 95% from $420K in FY2024; gross margin improved to 92.3% from 90.0%.
Catheter Precision acquires 80% of Fly Flyte and Ponderosa Air for $11.6M; raises up to $39M in PIPE
Acquisition of 80.02% of Fly Flyte, Inc. and 100% of Ponderosa Air from Creatd for $11.55M in cash and Series D preferred stock.
CEO David Jenkins exchanged royalty rights for ~9,490 shares of Series J Preferred Stock convertible into 6,083,005 common shares at $1.56, subject to stockholder approval.
Catheter Precision raises $2.18M in private placement, acquires 19.98% stake in FLYTE for $5.25M
Initial closing of private placement yields $2.18M; additional closings could raise up to ~$44.6M total.
Catheter Precision extends maturity of $1.5M in 8% promissory notes to 2028-2029
Extended $500k note from CEO David A. Jenkins matured Jan 31, 2026, now due Jan 31, 2029.
Catheter Precision terminates ATM equity facility after selling ~$4.0M of $4.3M
Terminated ATM agreement with Ladenburg Thalmann effective November 24, 2025; no penalties.
Catheter Precision Q3 revenue up 135% to $226K; net loss down 45% to $2.25M
Total revenue Q3 2025: $226K, +135% YoY from $96K; nine-month revenue $581K, +114%.
Shareholders approve increase in authorized shares to 500M for Catheter Precision
Special meeting on Oct 10, 2025 had 43.1% quorum (641,616 of 1,487,266 shares outstanding).
Catheter Precision secures UK approval for LockeT; partners with distributor HC21
LockeT suture retention device approved for commercialization in the UK; received CE Mark in May 2025.
Catheter Precision effects 1-for-19 reverse stock split effective August 15, 2025
Reverse stock split at ratio of 1-for-19; effective 12:01 a.m. ET on August 15, 2025.
Catheter Precision Q2 revenue up 128% YoY to $212K; net loss $5.4M with $3.2M non-cash
Revenue $212K for Q2 2025 vs $93K in Q2 2024, 128% increase; sequential growth 48%.
Catheter Precision announces 1-for-19 reverse stock split effective August 15, 2025
Reverse split ratio of 1-for-19 approved by board after shareholder authorization at July 25 annual meeting.
Catheter Precision sees record Q2 LockeT sales; Italy distributor secured
Q2 2025 LockeT sales on track to be highest to date, outpacing Q2 2024 by more than $84,000.
Catheter Precision Board approves warrant to Ladenburg Thalmann for 257,143 shares at $0.5424
Warrant issued to Ladenburg Thalmann as partial compensation for pipe financing closed May 12, 2025.
Catheter Precision terminates Chief Commercial Officer; CEO assumes role temporarily
Marie-Claude Jacques' employment as CCO discontinued effective June 2, 2025.
Catheter Precision details pro forma dilution to new investors at $1.25/share in ATM offering
Historical net tangible book value as of Mar 31, 2025: $(15.8)M or $(1.71)/share; after offering: $(14.6)M or $(0.95)/share.
Catheter Precision Q1 revenue up 74% to $143K, net loss $4.0M; cash $450K
Revenue $143K vs $82K YoY (+74%); net loss $4.0M including $1.2M non-cash charges.
Catheter Precision enters ATM agreement to sell up to $1.3M of common stock
ATM agreement with Ladenburg Thalmann allows sale of up to $1.3M of common stock on NYSE American.
Catheter Precision raises $1.5M cash, issues 3,000 Series B Preferred shares and warrants
Series B Preferred: 3,000 shares at $1,000 stated value; 1,500 sold for $1.5M cash, 1,500 issued for QHSLab notes.
Cardionomix purchased CNPS System patents/trademarks for heart failure; closed May 5, 2025.
Catheter Precision acquires heart failure device assets; Q1 revenue up 73% to $142k
Subsidiary Cardionomix buys patents/trademarks for Cardionomic's CPNS System (acute decompensated heart failure).
Catheter Precision subsidiary seeks to buy heart-failure assets from Cardionomic
Subsidiary Cardionomix would acquire CPNS System assets for 1M restricted VTAK shares and $1.5M promissory note.
Catheter Precision FY2024 revenue $420K, net loss $16.6M; Q4 rev $149K up 55% QoQ
Full year 2024 revenue $420 thousand; Q4 2024 revenue $149 thousand, sequential increase of 55% over Q3.
Catheter Precision furnishes March 2025 investor presentation; no details available
Company filed an investor presentation dated March 2025 as Exhibit 99.1.
Catheter Precision awards 700,000 incentive stock options to CEO and CCO at $0.42
CEO David Jenkins received options for 450,000 shares; 90,000 vested immediately, 120,000 vest each Jan 2026–2028.
Approved issuance of up to 10.7M shares upon exercise of Series K Warrants; 1.4M for, 833K against, 1.9M broker non-votes.
Catheter Precision appoints Philip Anderson as CFO, grants 500K stock options
Philip Anderson appointed CFO effective Jan 6, 2025, replacing interim CFO Margrit Thomassen who becomes Controller.
Catheter Precision posts Q3 net loss $4.1M, revenue $96K; warrants raise $4.9M
Sales revenue for Q3 2024 was ~$96K, net loss $4.1M (including $1.7M non-cash charges); nine-month net loss $11.0M.
Catheter Precision reprices seven warrant series to $0.70, expects $3.7M from inducement exercises
Reduced exercise price of Series E, F, G, H, I warrants from $1.00/$30/$40 to $0.70 per share on Oct 24, 2024.
Waiver granted to Jenkins Family Charitable Institute (trustee is CEO's daughter) to exercise 235,000 pre-funded warrants fully.
Catheter Precision raises $4.9M gross via warrant repricing; issues new Series K warrants
Total gross proceeds of $4.9M, including $3.7M from warrant repricing and $1.185M from prior exercises.
Catheter Precision closes $3.6M public offering with warrants; net proceeds ~$2.6M
Offering comprised of 805,900 common units at $1.00/unit and 2,773,000 pre-funded units at $0.9999/unit.
Catheter Precision amends $1.5M promissory notes: maturity to Jan 2026, rate to 12%
Extended maturity of five 8% short-term notes from Aug 30, 2024 to Jan 31, 2026.
Catheter Precision Q2 revenue $93K, net loss $4.2M; cash only $16K at June 30
Q2 revenue $93K, H1 $175K; net loss Q2 $4.2M, H1 $6.9M.
Catheter Precision borrows $500K from CEO-related trust at 8%, due Aug 30, 2024
Jenkins Family Charitable Institute (CEO David A. Jenkins is settlor, his daughter is trustee) lends $500K via 8% promissory note maturing Aug 30, 2024.
Catheter Precision converts all Series A Preferred; no shares remain outstanding
On July 23, 2024, 400 Series A Preferred shares converted into 25,000 common shares.
Catheter Precision gets $100K CEO loan at 8% due Aug 30, 2024, adding to prior $900K
Entity controlled by CEO David Jenkins loans $100,000 via 8% promissory note due August 30, 2024.
Catheter Precision files 1-for-10 reverse stock split; effective July 15, 2024
Reverse split ratio of 1-for-10; shares outstanding reduce from ~9.0M to ~901k.
Catheter Precision shareholders approve reverse stock split, authorize share decrease
James Caruso and Andrew Arno elected as Class III directors with ~2.6M votes each.
Catheter Precision reports Q2 revenue of $94,840; approves 1-for-10 reverse stock split
Preliminary Q2 2024 revenue $94,840, including first LockeT sales ($40,500) and VIVO ($54,340).
Catheter Precision receives $250K 8% note from CEO entity due Aug 30, 2024
Entity controlled by CEO David A. Jenkins loans $250K at 8% interest, maturing August 30, 2024.
Catheter Precision secures $150K 8% short-term note from CEO's entity due Aug 30, 2024
CEO David A. Jenkins' entity FatBoy Capital LP loans $150,000 at 8% interest, maturing August 30, 2024.
CEO loans Catheter Precision $500K at 8%; enters royalty agreement for LockeT device
CEO David Jenkins loaned $500,000 via 8% promissory note due August 30, 2024.
Director John P. Francis will not stand for reelection at July 3, 2024 Annual Meeting
John P. Francis informed Board he will not stand for reelection at the 2024 Annual Meeting on July 3, 2024.
Catheter Precision Q1 2024 revenue $82K, net loss $2.7M; cash drops to $0.5M
Q1 2024 revenue of $82,000; net loss of $2.7 million.
Catheter Precision files revised auditor consent correcting registration statement references
Original consent in 2023 10-K mistakenly referenced Form S-3 333-269491 and Amendment No.1 333-270919.
Mr. David Jenkins, the Company’s Executive Chairman of the Board and Chief Executive Officer, will fill the role of Chief Commercial Officer until a replacement is engaged.
On June 2, 2025, Catheter Precision, Inc. (the “Company”) discontinued the employment of Marie-Claude Jacques, the Company’s Chief Commercial Officer.
On January 4, 2025, the Board of Directors of Catheter Precision, Inc. (the “Company”) appointed Philip Anderson as Chief Financial Officer of the Company, effective January 6, 2025.
Ms. Margrit Thomassen, the Company’s previous Interim Chief Financial Officer, ceased serving in that capacity on January 6, 2025 and will continue in the role of Company Controller.
On May 15, 2024, John P. Francis informed the Board of Directors of Catheter Precision, Inc. (the “Company”) that he would not stand for reelection to the Board of Directors of the Company at the Company’s 2024 Annual Meeting of Stockholders scheduled for July 3, 2024.
Effective January 2, 2024 (the “Effective Date”), the Board of Directors (the “Board”) of the registrant, Catheter Precision, Inc. (the “Company”), has appointed John P. Francis to serve as a Class III director
Also as of the Effective Date, the Board has named David Jenkins Chief Executive Officer of the Company.
His appointment fills the vacancy created by the previously reported resignation of Susanne Meline that occurred on December 28, 2023.
Ms. Thomassen replaces Steve Passey, whose employment was terminated on December 28, 2023, effective December 31, 2023.
In addition, the Board has named Margrit Thomassen, age 53, to serve as interim Chief Financial Officer and Secretary as of the Effective Date.
On December 28, 2023, Susanne Meline tendered her resignation from the Board of Directors of Catheter Precision, Inc. (the “Company”), effective immediately.
Until a new Chief Executive Officer is identified, David Jenkins, Executive Chairman of the Board, will serve as interim Chief Executive Officer and as the Company’s principal executive officer, effective April 28, 2023.
Max materiality 0.85 · Median 0.60 · Most common event other_material